SciLogica
SciLogica Corp is a US-based life-sciences company developing the Elucido™ optical platform for continuous, real-time blood analyte monitoring during extracorporeal therapies (CRRT, OT, CPB) in hospital settings. The product is pre-commercial and not yet cleared for sale.
- Company typePrivate
- Founded2019
- HeadquartersDenver, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What SciLogica does
SciLogica Corp is a Delaware-incorporated, US-based life-sciences company founded in 2019 and headquartered in Denver, developing the Elucido™ platform — an optical (light-based) sensing system intended to provide continuous, real-time measurement of blood analytes in extracorporeal blood treatment circuits. The platform is designed to integrate with CRRT (Continuous Renal Replacement Therapy), OT (Oxygenation Therapy), and CPB (Cardiopulmonary Bypass) systems in both semi-integrated and fully integrated configurations, enabling hospital medical teams to replace intermittent blood testing with continuous monitoring during extracorporeal therapies. SciLogica states in-house capabilities spanning concept inception, prototype creation, preclinical and clinical trials, and cleanroom manufacturing, and holds a registered trademark for "ELUCIDO."
SciLogica firmographics
Firmographics- Name
- SciLogica
- Legal name
- SciLogica Corp
- Website
- https://scilogicacorp.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- SciLogica Corp is a US-based life-sciences company developing the Elucido™ optical platform for continuous, real-time blood analyte monitoring during extracorporeal therapies (CRRT, OT, CPB) in hospital settings. The product is pre-commercial and not yet cleared for sale.
- Ownership category
- akta.pro rank
SciLogica industry classification
Industry- Product category
- Medical Device – Continuous Blood Analyte Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
Keywords
Where SciLogica is headquartered
LocationHeadquarters
- HQ city
- Denver
- HQ country
- United States
- HQ region
- North America
Markets served
SciLogica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Medical Device Platform Sales: Pre-revenue company developing the Elucido™ platform for continuous blood analyte monitoring. The company is in development stage with products not yet cleared for sale in any markets. Regulatory clearance submissions are planned for the future.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
SciLogica product offering
Product offeringCore offering
SciLogica develops the Elucido™ platform, a medical device that uses optical/light-based sensing technology to deliver continuous, real-time measurement of blood analytes. The platform is designed to integrate with extracorporeal blood treatment systems including Continuous Renal Replacement Therapy (CRRT), Oxygenation Therapy (OT), and Cardiopulmonary Bypass (CPB), enabling medical teams to make fast, life-saving decisions based on real-time data. The product is currently in development and has not yet been cleared for sale in any market.
Product overview
SciLogica offers the Elucido™ platform as its core product offering. This platform enables continuous monitoring of blood analytes using light-based sensing technology. The system integrates with various extracorporeal blood treatment systems to deliver real-time, accurate measurements, allowing medical teams to improve patient outcomes and reduce hospital costs. The platform supports semi-integrated and fully integrated deployment configurations.
Differentiator
Problem solved
Functional benefit
Brands
- Elucido™: Continuous measurement platform for blood analytes using light-based technology, enabling real-time, accurate blood analyte measurements for improved patient outcomes and reduced hospital costs.
Products and services
- Elucido™ Platform A platform technology using optical/light-based sensing to provide continuous, real-time measurement of blood analytes. Designed for integration with extracorporeal blood treatment systems such as CRRT (Continuous Renal Replacement Therapy), OT (Oxygenation Therapy), and CPB (Cardiopulmonary Bypass), supporting both semi-integrated and fully integrated solutions. Targeted at hospital medical teams needing real-time clinical data.
Quantifiable outcome
- Improved patient outcomes through real-time monitoring
- +1 more outcomes
Companies that use SciLogica
Customer profileSegments1 record
Ideal customer profiles1 record
SciLogica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
SciLogica partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
SciLogica competitors and assessment
Company assessmentBroad incumbents
- Fresenius Medical Care: Fresenius is the global leader in dialysis and CRRT systems (e.g., multiFiltrate, FX CorDiax) - directly comparable to SciLogica's CRRT integration target. As an incumbent with installed base, OEM relationships, and adjacent patient monitoring capabilities, Fresenius represents both a potential integration partner and a competitive threat for hospital procurement budgets.
- Baxter International: Baxter's PrisMax and AK 98 systems are leading CRRT platforms with integrated monitoring features. As a major critical-care device manufacturer with global hospital relationships, Baxter is directly comparable as both an OEM partner candidate and a competitor with internal monitoring capabilities for the same clinical workflow SciLogica targets.
- Terumo Corporation: Terumo manufactures CPB (cardiopulmonary bypass) and ECMO systems through its Terumo Cardiovascular and Terumo BCT divisions. As the dominant supplier of heart-lung machines in cardiac surgery, Terumo is a natural integration partner for Elucido in the CPB use case and a comparable in the extracorporeal blood treatment ecosystem.
- Medtronic: Medtronic's Cardiac Surgery division (formerly Medtronic Perfusion Systems) supplies CPB consoles and physiological monitoring for cardiopulmonary bypass procedures. Comparable as an OEM partner for the CPB integration pathway and as a broader medtech incumbent with R&D capacity to develop or acquire competing blood analyte monitoring technology.
- Abbott Point of Care: Abbott's i-STAT system is the dominant handheld blood analyte analyzer in hospitals and ambulatory settings. While currently a discrete cartridge-based product, i-STAT represents the competitive benchmark for rapid blood analyte measurement that SciLogica's continuous optical sensing approach aims to disrupt.
- Edwards Lifesciences: Edwards Lifesciences' Critical Care division provides hemodynamic and blood parameter monitoring (e.g., FloTrac, HemoSphere) used in cardiac surgery and ICU settings including during CPB and ECMO. Comparable as a major incumbent in continuous patient monitoring with the hospital relationships and clinical evidence infrastructure SciLogica will need to compete against.
Direct peers
- Nova Biomedical: Nova Biomedical manufactures blood gas and analyte analyzers (e.g., Stat Profile Prime) used in critical care and point-of-care settings, including devices that integrate with CRRT systems. Directly comparable as a developer of blood analyte measurement technology targeting the same hospital clinical workflows SciLogica addresses.
Emerging players
- Spectral Medical: Spectral Medical develops therapeutic hemoperfusion and extracorporeal blood treatment diagnostics, including PMX (polymyxin B hemoperfusion) with companion diagnostic components. Comparable as a smaller, focused player in the extracorporeal blood treatment monitoring space with similar regulatory pathway dynamics.
- CytoSorbents Corporation: CytoSorbents develops blood purification and extracorporeal cytokine adsorption technology used in CRRT/ECMO circuits. Comparable as a smaller medtech focused on enhancing extracorporeal blood treatment through additive sensor/therapeutic technologies integrated with the same device platforms SciLogica targets.
- Outset Medical: Outset Medical's Tablo Hemodialysis System includes integrated real-time monitoring of treatment parameters and is expanding into CRRT markets. Comparable as an emerging medtech that has demonstrated the commercial viability of integrated monitoring within a dialysis/CRRT-adjacent workflow, providing a relevant go-to-market template.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
SciLogica social profiles
Digital presenceSciLogica financial estimates
Financial estimateRevenue estimate
Valuation estimate
SciLogica leadership team
Management profileNumber of profiles
Profiles3 records
SciLogica funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SciLogica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SciLogica
What does SciLogica do?
SciLogica develops the Elucido™ platform, a medical device that uses optical/light-based sensing technology to deliver continuous, real-time measurement of blood analytes. The platform is designed to integrate with extracorporeal blood treatment systems including Continuous Renal Replacement Therapy (CRRT), Oxygenation Therapy (OT), and Cardiopulmonary Bypass (CPB), enabling medical teams to make fast, life-saving decisions based on real-time data. The product is currently in development and has not yet been cleared for sale in any market.
Is SciLogica a public or private company?
SciLogica is a private company. It is classified as venture growth investor backed and is currently operating.
When was SciLogica founded?
SciLogica was founded in 2019. It employs 251 to 500 people.
Where is SciLogica based?
SciLogica is headquartered in Denver, United States, in the North America region.
How does SciLogica make money?
One revenue line is on record: medical Device Platform Sales.
Who are SciLogica's main competitors?
Broad incumbents on record are Fresenius Medical Care, Baxter International, Terumo Corporation, Medtronic, Abbott Point of Care and Edwards Lifesciences. Nova Biomedical is listed as a direct peer. Emerging players are Spectral Medical, CytoSorbents Corporation and Outset Medical.
Does SciLogica have an API?
No public API is recorded for SciLogica.
What industry is SciLogica in?
SciLogica's product category is Medical Device – Continuous Blood Analyte Monitoring. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3845.